drugset / Trial / NCT03710642

Prazosin for Agitation in Alzheimer's Disease

NCT03710642

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion

Timeline

Start
2018-10-23
Primary completion
2022-01-05
Completion
2022-01-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prazosin Unknown 4 mg Oral
Comparator Prazosin Unknown 6 mg Oral